// App-Quantinova.ai

3059 : Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.

Researchers

Presenter

  • Roy S. Herbst

Principal Investigators

  • Daniel Peter Petrylak

  • Hendrik-Tobias Arkenau

  • Johanna C. Bendell

  • Rafael Santana-Davila

  • Emiliano Calvo

  • Nicolas Penel

  • Juan Martin-Liberal

  • Andres O. Soriano

  • Philippe Alexandre Cassier

  • Matthew Krebs

  • Nicolas Isambert

  • Ryan Widau

  • Gu Mi

  • Jin Jin

  • David Raymond Ferry

  • Charles S. Fuchs

  • Luis G. Paz-Ares

Medical Centers

  • Yale University School of Medicine, New Haven, CT

  • The Royal Marsden Hospital, London, United Kingdom

  • Yale University School of Medicine, New Haven, CT

  • Sarah Cannon Research Institute, London, United Kingdom

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • University of Washington, Seattle, WA

  • START Madrid, CIOCC, Madrid, Spain

  • Oscar Lambret Center, Lille, France

  • Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain and Catalan Institute of Oncology (ICO) Hospitalet, Barcelona, Spain

  • Florida Cancer Specialists, Tavares, FL

  • Centre Leon Berard, Lyon, France

  • The Christie NHS Foundation Trust and The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

  • Service d'oncologie medicale CLCC Georges-Francois Leclerc, Dijon, France

  • Eli Lilly and Company, Indianapolis, IN

  • Eli Lilly and Company, New York, NY

  • Smilow Cancer Hospital at Yale-New Haven, New Haven, CT

  • University Hospital 12 de October, Madrid, Spain

Locations

  • United States

  • Spain

  • France

  • United Kingdom

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

  • Ramucirumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02443324

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved